Breaking News Instant updates and real-time market news.

MSCC

Microsemi

$52.18

-0.23 (-0.44%)

, MU

Micron

$25.38

-0.26 (-1.01%)

07:25
03/09/17
03/09
07:25
03/09/17
07:25

Susquehanna to hold a conference

6th Annual Semi, Storage & Technology Conference is being held in New York on March 9.

MSCC

Microsemi

$52.18

-0.23 (-0.44%)

MU

Micron

$25.38

-0.26 (-1.01%)

IMPV

Imperva

$42.45

0.8 (1.92%)

CHKP

Check Point

$99.80

1.12 (1.14%)

CTXS

Citrix

$79.92

0.02 (0.03%)

HDP

Hortonworks

$9.86

-0.03 (-0.30%)

JCOM

j2 Global

$82.86

0.64 (0.78%)

MXL

MaxLinear

$26.19

0.14 (0.54%)

NVI

National Vision, Inc.

OLN

Olin Corp.

$31.88

-0.05 (-0.16%)

  • 09

    Mar

  • 10

    Mar

  • 12

    Mar

  • 14

    Mar

  • 20

    Mar

  • 23

    Mar

  • 04

    Apr

  • 05

    Apr

MSCC Microsemi
$52.18

-0.23 (-0.44%)

01/30/17
RBCM
01/30/17
NO CHANGE
RBCM
Microsemi could benefit from higher defense spending, says RBC Capital
RBC Capital analyst Mitch Steves is more upbeat on Microsemi's Aerospace and Defense unit, given GOP dominance in Washington. The analyst expects the company to benefit more from higher defense spending than any other name he covers. Steves raised his price target on the shares to $64 from $56 and keeps a Top Pick rating on the stock.
01/27/17
RHCO
01/27/17
NO CHANGE
RHCO
Microsemi should be bought on weakness, says SunTrust
After Microsemi reported in-line Q4 results and the stock fell slightly in pre-market trading, SunTrust analyst William Stein says that the company's results are "good and getting better." Among the positive aspects of its results are improving margins, organic revenue growth ,and debt load reduction, according to the analyst.
01/05/17
RBCM
01/05/17
NO CHANGE
RBCM
Microsemi remains a Top Pick at RBC Capital
RBC Capital said Microsemi remains a Top Pick following meetings at CES and believes the company remains a premier strategic asset and should see a material amount of interest over the next 12 months. RBC rates Microsemi a Top Pick with a $64 price target.
01/06/17
SPHN
01/06/17
NO CHANGE
Target $63
SPHN
Overweight
Microsemi remains an 'attractive acquisition target,' says Stephens
Following Consumer Electronics Show's first day, Stephens analyst Harsh Kumar notes that Microsemi's overall business appears to be good and the company expects to be on track for its organic growth target of 6%-8% during 2017. Furthermore, the analyst continues to believe that Microsemi remains an "attractive acquisition" target with a likely take out price of $55-$60. He reiterates an Overweight rating and $63 price target on the shares.
MU Micron
$25.38

-0.26 (-1.01%)

03/01/17
03/01/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Micron (MU) upgraded to Buy from Neutral at Goldman with analyst Mark Delaney saying the potential for near-term earnings upside from better margins presents a "tactical opportunity." 2. Owens Corning (OC) upgraded to Buy from Neutral at BofA/Merrill with analyst John Lovallo citing increased confidence that industry is operating line capacity utilization could increase to the mid-90% range in the second half 2017/2018 from roughly 90% today. Following management meetings yesterday, Lovallo raised estimates to reflect increased confidence in a positive price inflection in the insulation business and said Composites pricing could rise more than expected in 2017. 3. Williams (WMB) upgraded to Conviction Buy from Buy at Goldman with analyst Theodore Durbin citing the 38% total return potential to his unchanged price target of $38. The market is not appreciating the company's "visible, low-risk" organic growth and "strong" free cash flow generation, Durbin tells investors in a research note. 4. GMS Inc. (GMS) upgraded to Outperform from Neutral at Baird with analyst David Manthey citing continued construction tailwinds, industry share gains, solid operating leverage potential and strong M&A activity. Manthey raised his price target to $36 from $32. 5. Marvell (MRVL) upgraded to Neutral from Sell at Goldman with analyst Mark Delaney citing improved hard disk drive demand trends. The analyst believes consensus estimates can move higher when Marvell reports results on March 2 and upped his price target for the shares to $16 from $12. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/02/17
GSCO
03/02/17
NO CHANGE
GSCO
Buy
Micron positive preannouncement supports near-term earnings upside, says Goldman
Goldman analyst Mark Delaney said Micron's positive preannouncement supports his view of near-term earnings upside from better margins. Delaney expects additional earnings upside in the May and August quarters given the timing lag for better market pricing to impact contracts. The analyst has a Buy rating and a $29 price target on Micron shares.
03/02/17
STFL
03/02/17
NO CHANGE
Target $40
STFL
Buy
Micron price target raised to $40 from $34 at Stifel
Stifel analyst Kevin Cassidy raised his price target on Micron to $40 after the company raised its guidance for its Q2 earnings, revenue and gross margin. The firm has a Buy rating on Micron shares.
03/02/17
NEED
03/02/17
NO CHANGE
Target $42
NEED
Buy
Micron price target raised to $42 from $33 at Needham
Needham analyst Rajvindra Gill raised his price target on Micron to $42 following the company's positive preannouncement.
IMPV Imperva
$42.45

0.8 (1.92%)

02/09/17
BTIG
02/09/17
INITIATION
BTIG
Neutral
Imperva initiated with a Neutral at BTIG
After Imperva delivered beat and raise results, BTIG analyst Joel Fishbein called the results "solid." The analyst ,however, thinks the company still has "issues" to deal with over the longer term, and he does not think that the stock can rise significantly beyond current levels, even if the company becomes a takeover target.
02/10/17
IMPC
02/10/17
NO CHANGE
Target $55
IMPC
Outperform
Imperva price target raised to $55 from $50 at Imperial Capital
Imperial Capital analyst Michael Kim raised his price target on Imperva to $55 from $50, stating after the company's earnings report that he is encouraged by its "significantly improved execution" under new sales leadership. Kim, who expects reduced headwinds from product revenue due to improved sales execution along with continued strong growth in subscription revenue, keeps an Outperform rating on Imperva shares.
02/09/17
EVER
02/09/17
NO CHANGE
Target $56
EVER
Buy
Imperva price target raised to $56 from $45 at Evercore ISI
Evercore ISI analyst Ken Talanian said Imperva reported strong results and guidance that reflects both continued growth and margin expansion and sees further upside to shares despite 9%+ aftermarket strength. The analyst is encouraged that the company saw a resurgence of large deals that were partly driven by the company's subscription offerings. Talanian remains Buy rated on Imperva and raised its price target to $56 from $45.
02/09/17
JMPS
02/09/17
NO CHANGE
JMPS
Imperva price target raised to $56 from $46 at JMP Securities
JMP Securities analyst Erik Suppiger raised his price target on Imperva after the company's beat and raise results. The analyst thinks that the company's valuation remains attractive, and he keeps an Outperform rating on the shares.
CHKP Check Point
$99.80

1.12 (1.14%)

01/20/17
BMOC
01/20/17
NO CHANGE
BMOC
Check Point reported 'solid' results, says BMO Capital
BMO Capital analyst Keith Bachman says that Check Point (CHKP) reported "solid all-around" results, as its results were "solid.. on almost every metric." In the wake of the results, Bachman raised his price target on Check Point to $110 from $95, and he raised his billings estimates for Palo Alto (PANW) and Fortinet (FTNT). The analyst keeps a Market Perform rating on Check Point and says that the risk/reward ratios for Palo Alto (PANW) and Fortinet (FTNT) are more favorable than that of Check Point.
02/03/17
JMPS
02/03/17
NO CHANGE
Target $41
JMPS
Outperform
Fortinet price target raised to $41 from $34 at JMP Securities
JMP Securities analyst Erik Suppiger raised his price target on Fortinet (FTNT) to $41 from $34 following the company's quarterly report, the highlight of which he considers the company's strong billings and billings guidance. Additionally, Suppiger thinks the strength from both Check Point (CHKP) and Fortinet shows that the firewall market improved in Q4, which he said bodes well for Palo Alto Networks (PANW). The analyst keeps an Outperform rating on Fortinet shares.
02/06/17
BTIG
02/06/17
UPGRADE
BTIG
Buy
Check Point upgraded to Buy from Neutral at BTIG
02/07/17
BTIG
02/07/17
UPGRADE
Target $118
BTIG
Buy
Check Point upgraded to Buy with $118 target at BTIG
BTIG analyst Joel Fishbein last night upgraded Check Point Software Technologies to Buy from Neutral with a $118 price target. The shares closed yesterday down 44c to $98.96. The significant increase in threats, data breaches and customer spending on network security should drive revenue growth, Fishbein tells investors in a research note. He believes the stock has further room to run despite the 18% year-to-date rise.
CTXS Citrix
$79.92

0.02 (0.03%)

01/10/17
WELS
01/10/17
INITIATION
WELS
Market Perform
Citrix initiated with a Market Perform at Wells Fargo
Wells Fargo analyst Philip Winslow started Citrix Systems with a Market Perform rating and $100-$105 price target range.
02/28/17
BARD
02/28/17
DOWNGRADE
Target $85
BARD
Neutral
Citrix assumed with Neutral at Baird
Baird analyst Rob Oliver assumed coverage on Citrix with a Neutral and $85 price target.
12/15/16
SBSH
12/15/16
NO CHANGE
Target $116
SBSH
Buy
Citi positive on core Citrix growth, ups target to $116
Citi analyst Walter Pritchard raised his price target for Citrix Systems to $116 from $113 and keeps a Buy rating on the shares. The analyst came away with "largely positive conclusions" after analyzing the company's core growth given the imminent separation of GetGo. Pritchard believes Citrix's growth potential is being underappreciated by investors.
12/08/16
BARD
12/08/16
INITIATION
Target $108
BARD
Neutral
LogMeln initiated with a Neutral at Baird
Baird analyst William Power initiated LogMeIn (LOGM) with a Neutral rating and $108 price target. Power acknowledged its attractive free cash flow but sees valuation and integration risk with its acquisition of Citrix's (CTXS) GoTo division.
HDP Hortonworks
$9.86

-0.03 (-0.30%)

10/13/16
GSCO
10/13/16
DOWNGRADE
Target $7
GSCO
Sell
Hortonworks downgraded to Sell from Buy at Goldman
Goldman analyst Jesse Hulsing downgraded Hortonworks two notches to Sell from Buy and lowered its price target to $7 from $13. The analyst his previous thesis of sustained growth from ongong Hadoop adoption and improved efficiency due to higher mix of expansions was wrong. He expects increased competition for new analytics workloads from cloud services vendors will challenge Hortonworks' pure open source business model and is concerned that FY17 Street billings estimates are too high.
01/30/17
MZHO
01/30/17
UPGRADE
Target $12
MZHO
Buy
Hortonworks upgraded to Buy at Mizuho
As previously reported, Mizuho upgraded Hortonworks to Buy from Neutral and increased its price $12 from $10. Analyst Abney Lamba said oil field checks indicate industry adoption remains strong and pricing is showing signs of improvement. The analyst believes Hortonwork risk/reward is attractive and expects Q4 results to be above estimates.
01/10/17
WELS
01/10/17
INITIATION
WELS
Outperform
Hortonworks initiated with an Outperform at Wells Fargo
Wells Fargo analyst Philip Winslow started Hortonworks with an Outperform rating and $13-$15 price target range.
01/29/17
MZHO
01/29/17
UPGRADE
MZHO
Buy
Hortonworks upgraded to Buy from Neutral at Mizuho
JCOM j2 Global
$82.86

0.64 (0.78%)

08/31/16
08/31/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BTIG initiated coverage of Juno Therapeutics (JUNO) with a Sell rating, saying the firm is "generally skeptical of current investor expectations for the CD19 CAR T market." The firm has a fair value estimate on Juno of $23 per share. 2. JPMorgan analyst Alex Yao assumed coverage of Sohu.com (SOHU) with an Underweight rating and $40 price target. The rating is unchanged and the price target is lowered from $47. The company will find it difficult to come up with new initiatives to address the continued decline in games revenue, Yao tells investors in a research note. 3. JPMorgan's Yao assumed coverage of SINA (SINA) with an unchanged Overweight rating and $123 price target. 4. Jefferies analyst Jason Kupferberg started First Data (FDC) with a Buy rating and $16.50 price target. Growth in the company's domestic merchant processing segment is set to inflect, the analyst tells investors in a research note. 5. Baird analyst William Power initiated j2 Global (JCOM) with an Outperform rating and $83 price target, citing its attractive valuation, strong free cash flow, consistent margin expansion, the growth in digital media, and its disciplined acquisition strategy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/21/16
SBSH
10/21/16
DOWNGRADE
Target $10.5
SBSH
Neutral
Everyday Health downgraded to Neutral from Buy at Citi
Citi analyst Mark Kelley downgraded Everyday Health (EVDY) to Neutral after the company announced an agreement with j2 Global's (JCOM) Ziff Davis to be acquired for $10.50 per share in cash. The analyst views the price as fair and does not expect WebMD (WBMD) to come in with a competing bid.
10/24/16
LEER
10/24/16
DOWNGRADE
Target $10.5
LEER
Market Perform
Everyday Health downgraded to Market Perform from Outperform at Leerink
Leerink analyst David Larsen downgraded Everyday Health (EVDY) to Market Perform from Outperform after the company announced that it has entered into a definitive agreement to merge with Ziff Davis, the digital media division of j2 Global (JCOM) in an all cash deal. The analyst also lowered his price target on the stock to $10.50 from $13, as he expects the shares to trade at or around the deal price.
01/25/17
SBSH
01/25/17
DOWNGRADE
Target $88
SBSH
Neutral
j2 Global downgraded to Neutral from Buy at Citi
Citi analyst Walter Pritchard downgraded j2 Global (JCOM) to Neutral citing valuation. The analyst believes the shares at current levels reflect the Everyday Health (EVDY) accretion potential. He keeps an $88 price target for the j2.
MXL MaxLinear
$26.19

0.14 (0.54%)

12/20/16
SUSQ
12/20/16
INITIATION
Target $26
SUSQ
Positive
MaxLinear initiated with a Positive at Susquehanna
Susquehanna analyst Christopher Rolland initiated MaxLinear with a Positive and a $26 price target.
08/09/16
DBAB
08/09/16
NO CHANGE
Target $25
DBAB
Buy
MaxLinear pullback a buying opportunity, says Deutsche Bank
Deutsche Bank analyst Ross Seymore recommends using the post-earnings pullback in shares of MaxLinear as a buying opportunity. The company's quarter was solid but its Q3 outlook reflected a faster than expected fall-off of its legacy video SoC business and lesser benefits from recent acquisitions, Seymore tells investors in a post-earnings research note. Estimates are now "significantly de-risked" and the company's underlying growth drivers should become increasingly apparent heading into 2017, the analyst contends. He lowered his price target for MaxLinear to $25 from $30 and keeps a Buy rating on the shares.
02/06/17
ROTH
02/06/17
NO CHANGE
Target $30
ROTH
Buy
MaxLinear price target raised to $30 from $24 at Roth Capital
Roth Capital analyst Brian Alger raised his price target for MaxLinear to $30 from $24 ahead of results. The analyst believes the Street has absorbed the transition away from the legacy declining businesses and is looking forward to the growth coming from multiple infrastructure drivers. He reiterates a Buy rating on the shares.
NVI National Vision, Inc.

OLN Olin Corp.
$31.88

-0.05 (-0.16%)

11/02/16
RBCM
11/02/16
NO CHANGE
RBCM
Olin Corp. 2017 outlook enocuraging, says RBC Capital
After Olin reported higher than expected Q3 EBITDA but provided lower than expected 2017 EBITDA guidance, RBC Capital analyst Arun Viswanathan thinks that the company's 2017 outlook is encouraging. He says that the company will benefit from synergies and strong cash flow next year, while higher caustic prices could enable its results to beat expectations in 2017. The analyst says that patient investors could be rewarded by buying the stock. He raised his price target on the name to $25 from $24 and keeps an Outperform rating on the stock.
02/02/17
LBOW
02/02/17
UPGRADE
LBOW
Neutral
Olin Corp. upgraded to Neutral from Underperform at Longbow
02/02/17
MONN
02/02/17
DOWNGRADE
MONN
Neutral
Olin Corp. downgraded to Neutral from Buy at Monness Crespi
02/02/17
02/02/17
DOWNGRADE

Neutral
Olin Corp. downgraded to Neutral on valuation at Monness Crespi
As previously reported, Monness Crespi downgraded Olin Corp. to Neutral from Buy. Analyst Chris Shaw said shares have surpassed his prior target of $28 and believes valuation reflects much of the upside in 2017.

TODAY'S FREE FLY STORIES

13:45
05/24/17
05/24
13:45
05/24/17
13:45
General news
Breaking General news story  »

FOMC Minutes to be…

ALNY

Alnylam

$74.87

0.94 (1.27%)

13:43
05/24/17
05/24
13:43
05/24/17
13:43
Recommendations
Alnylam analyst commentary  »

Alnylam share offering a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 06

    Jun

  • 24

    May

DB

Deutsche Bank

$18.90

-0.35 (-1.82%)

13:40
05/24/17
05/24
13:40
05/24/17
13:40
Hot Stocks
Democrats seek info on Trump loans, Russia mirror trading from Deutsche Bank »

Democratic lawmakers,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 07

    Jun

TCO

Taubman Centers

$62.63

1.61 (2.64%)

13:40
05/24/17
05/24
13:40
05/24/17
13:40
Options
Call buyer in Taubman Centers opens a notable new position »

Call buyer in Taubman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBYI

Puma Biotechnology

$57.80

5.2 (9.89%)

13:36
05/24/17
05/24
13:36
05/24/17
13:36
Hot Stocks
Puma Biotechnology trading to resume at 1:50 pm ET »

Quotation for Puma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 02

    Jun

  • 06

    Jun

  • 21

    Jul

PAA

Plains All American

$27.86

-0.0899 (-0.32%)

13:35
05/24/17
05/24
13:35
05/24/17
13:35
Options
Plains All American put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 08

    Aug

  • 08

    Nov

MSFT

Microsoft

$68.68

0.23 (0.34%)

, LNVGY

Lenovo

$12.52

-0.18 (-1.42%)

13:34
05/24/17
05/24
13:34
05/24/17
13:34
Hot Stocks
Microsoft introduces 'Windows 10 China Government Edition' »

As part of a media event…

MSFT

Microsoft

$68.68

0.23 (0.34%)

LNVGY

Lenovo

$12.52

-0.18 (-1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jun

HPQ

HP Inc.

$19.02

0.055 (0.29%)

, MSFT

Microsoft

$68.68

0.23 (0.34%)

13:33
05/24/17
05/24
13:33
05/24/17
13:33
Earnings
On The Fly: What to watch in HP Inc.'s earnings report »

HP Inc. (HPQ) is…

HPQ

HP Inc.

$19.02

0.055 (0.29%)

MSFT

Microsoft

$68.68

0.23 (0.34%)

INTC

Intel

$35.86

0.09 (0.25%)

AMZN

Amazon.com

$971.54

0.87 (0.09%)

GOOG

Alphabet

$948.82

6.96 (0.74%)

GOOGL

Alphabet Class A

$970.55

6.48 (0.67%)

IT

Gartner

$115.24

1.6099 (1.42%)

LNVGY

Lenovo

$12.52

-0.18 (-1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 31

    May

  • 01

    Jun

  • 01

    Jun

  • 06

    Jun

  • 08

    Jun

  • 12

    Jun

  • 28

    Jun

  • 19

    Jul

PBYI

Puma Biotechnology

13:31
05/24/17
05/24
13:31
05/24/17
13:31
Hot Stocks
Puma Biotechnology receives FDA advisory commitee support for neratinib »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 02

    Jun

  • 06

    Jun

  • 21

    Jul

TSLA

Tesla

$303.86

-6.49 (-2.09%)

13:28
05/24/17
05/24
13:28
05/24/17
13:28
Hot Stocks
Safety advocate says Tesla workers get injured more than industry rate »

Worksafe, which describes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 02

    Oct

GOOG

Alphabet

$948.82

6.96 (0.74%)

, GOOGL

Alphabet Class A

$970.55

6.48 (0.67%)

13:27
05/24/17
05/24
13:27
05/24/17
13:27
Hot Stocks
Google Fiber launches in Huntsville, company takes lease approach »

Google announced Tuesday…

GOOG

Alphabet

$948.82

6.96 (0.74%)

GOOGL

Alphabet Class A

$970.55

6.48 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 01

    Jun

  • 28

    Jun

  • 19

    Jul

OAS

Oasis Petroleum

$11.13

-0.3869 (-3.36%)

13:25
05/24/17
05/24
13:25
05/24/17
13:25
Options
Oasis Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 27

    Jun

13:25
05/24/17
05/24
13:25
05/24/17
13:25
General news
FOMC minutes preview: »

FOMC minutes preview: the…

FOLD

Amicus

$8.26

-0.15 (-1.78%)

13:25
05/24/17
05/24
13:25
05/24/17
13:25
Conference/Events
JPMorgan SMid biotech analyst holds an analyst/industry conference call »

SMid Biotech Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 13

    Jun

MSFT

Microsoft

$68.68

0.23 (0.34%)

, GME

GameStop

$22.54

-0.12 (-0.53%)

13:18
05/24/17
05/24
13:18
05/24/17
13:18
Hot Stocks
Microsoft says 'Xbox Game Pass' service launches June 1 »

Microsoft (MSFT)…

MSFT

Microsoft

$68.68

0.23 (0.34%)

GME

GameStop

$22.54

-0.12 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 31

    May

  • 08

    Jun

$NSD

NASDAQ Market Internals

13:17
05/24/17
05/24
13:17
05/24/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
05/24/17
05/24
13:16
05/24/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$10.50

0.175 (1.70%)

13:15
05/24/17
05/24
13:15
05/24/17
13:15
Options
Fiat Chrysler put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
05/24/17
05/24
13:15
05/24/17
13:15
General news
Treasury's $34 B 5-year sale was surprisingly strong »

Treasury's $34 B…

DYNT

Dynatronics

$3.10

0.0336 (1.10%)

13:10
05/24/17
05/24
13:10
05/24/17
13:10
Hot Stocks
Breaking Hot Stocks news story on Dynatronics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANF

Abercrombie & Fitch

$11.92

-0.28 (-2.30%)

, AEO

American Eagle

13:09
05/24/17
05/24
13:09
05/24/17
13:09
Periodicals
Cerberus, American Eagle work on joint offer for Abercrombie & Fitch, WSJ says »

Cerberus Capital and…

ANF

Abercrombie & Fitch

$11.92

-0.28 (-2.30%)

AEO

American Eagle

EXPR

Express

$7.86

-0.02 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 01

    Jun

  • 20

    Jun

ANF

Abercrombie & Fitch

$11.93

-0.27 (-2.21%)

13:07
05/24/17
05/24
13:07
05/24/17
13:07
Hot Stocks
Breaking Hot Stocks news story on Abercrombie & Fitch »

Abercrombie & Fitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 20

    Jun

EXPR

Express

$7.86

-0.02 (-0.25%)

, ANF

Abercrombie & Fitch

$11.95

-0.25 (-2.05%)

13:03
05/24/17
05/24
13:03
05/24/17
13:03
Periodicals
Breaking Periodicals news story on Express, Abercrombie & Fitch, American Eagle »

Express, other PE firms…

EXPR

Express

$7.86

-0.02 (-0.25%)

ANF

Abercrombie & Fitch

$11.95

-0.25 (-2.05%)

AEO

American Eagle

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 01

    Jun

  • 20

    Jun

ANF

Abercrombie & Fitch

$11.95

-0.25 (-2.05%)

13:03
05/24/17
05/24
13:03
05/24/17
13:03
Hot Stocks
Breaking Hot Stocks news story on Abercrombie & Fitch »

Abercrombie & Fitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 20

    Jun

AEO

American Eagle

$11.08

0.005 (0.05%)

, ANF

Abercrombie & Fitch

$11.95

-0.25 (-2.05%)

13:02
05/24/17
05/24
13:02
05/24/17
13:02
Periodicals
Breaking Periodicals news story on American Eagle, Abercrombie & Fitch »

Cerberus, American Eagle…

AEO

American Eagle

$11.08

0.005 (0.05%)

ANF

Abercrombie & Fitch

$11.95

-0.25 (-2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 20

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.